Foghorn Therapeutics Inc.

NasdaqGM FHTX

Foghorn Therapeutics Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -389.03%

Foghorn Therapeutics Inc. EBITDA Margin is -389.03% for the Trailing 12 Months (TTM) ending September 30, 2024, a -19.74% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Foghorn Therapeutics Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -324.89%, a 53.29% change year over year.
Foghorn Therapeutics Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -695.53%, a 93.26% change year over year.
Foghorn Therapeutics Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -10,326.25%, a 69.97% change year over year.
Foghorn Therapeutics Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -34,382.68%.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NasdaqGM: FHTX

Foghorn Therapeutics Inc.

CEO	Mr. Adrian H. B. Gottschalk
IPO Date	Oct. 23, 2020
Location	United States
Headquarters	500 Technology Square
Employees	116
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years